Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

被引:9
|
作者
Vij, Ravi [1 ]
Martin, Thomas G., III [2 ]
Nathwani, Nitya [3 ]
Fiala, Mark A. [1 ]
Gao, Feng [1 ]
Deol, Abhinav [4 ]
Buadi, Francis K. [5 ]
Kaufman, Jonathan L. [6 ]
Hofmeister, Craig C. [6 ,7 ]
Gregory, Tara K.
Berdeja, Jesus G.
Chari, Ajai
Rosko, Ashley E. [8 ]
机构
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Wayne State Univ, Detroit, MI USA
[5] Mayo Clin, Rochester, MN USA
[6] Emory Univ, Sch Med, Atlanta, GA USA
[7] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Sch Med, Atlanta, GA USA
[8] Colorado Blood Canc Inst, Denver, CO USA
关键词
D O I
10.1182/blood-2019-130644
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
602
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial
    Vij, Ravi
    Nathwani, Nitya
    Martin, Thomas G., III
    Fiala, Mark A.
    Deol, Abhinav
    Buadi, Francis K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Gregory, Tara
    Berdeja, Jesus G.
    Chari, Ajai
    Rosko, Ashley E.
    [J]. BLOOD, 2018, 132
  • [2] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
    Michael Slade
    Thomas G. Martin
    Nitya Nathwani
    Mark A. Fiala
    Michael P. Rettig
    Feng Gao
    Abhinav Deol
    Francis K. Buadi
    Jonathan L. Kaufman
    Craig C. Hofmeister
    Tara K. Gregory
    Jesus Berdeja
    Ajai Chari
    Ashley Rosko
    Ravi Vij
    [J]. Leukemia, 2022, 36 : 2917 - 2921
  • [3] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
    Slade, Michael
    Martin, Thomas G.
    Nathwani, Nitya
    Fiala, Mark A.
    Rettig, Michael P.
    Gao, Feng
    Deol, Abhinav
    Buadi, Francis K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Gregory, Tara K.
    Berdeja, Jesus
    Chari, Ajai
    Rosko, Ashley
    Vij, Ravi
    [J]. LEUKEMIA, 2022, 36 (12) : 2917 - 2921
  • [4] Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
    Rosinol, Laura
    Oriol, Albert
    Rios Tamayo, Rafael
    Jesus Blanchard, María
    Jarque, Isidro
    Bargay, Joan
    Hernandez, Miguel-Teodoro
    Maria Moraleda, Jose
    Carrillo-Cruz, Estrella
    Sureda, Anna
    Martinez-Lopez, Joaquin
    Krsnik, Isabel
    Gonzalez Garcia, Esther
    Casado, Felipe
    Marti, Josep M.
    Encinas, Cristina
    De Arriba, Felipe
    Palomera, Luis
    Sampol, Antonia
    Gonzalez-Montes, Yolanda
    Cabezudo, Elena
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Jose Lahuerta, Juan
    Blade Creixenti, Joan
    [J]. BLOOD, 2021, 138
  • [5] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma
    Kourelis, Taxiarchis
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Wolfe, Eric
    [J]. BLOOD, 2018, 132
  • [6] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
    Moreau, Philippe
    Hulin, Cyrille
    Caillot, Denis
    Marit, Gerald
    Perrot, Aurore
    Garderet, Laurent
    Facon, Thierry
    Benboubker, Lotfi
    Karlin, Lionel
    Tiab, Mourad
    Arnulf, Bertrand
    Fermand, Jean-Paul
    Leleu, Xavier
    Touzeau, Cyrille
    Roussel, Murielle
    Planche, Lucie
    Minvielle, Stephane
    Bene, Marie-Christine
    Avet-Loiseau, Herve
    Dejoie, Thomas
    Attal, Michel
    [J]. BLOOD, 2016, 128 (22)
  • [7] Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Patel, Krina K.
    Shah, Jatin J.
    Feng, Lei
    Lee, Hans C.
    Manasanch, Elisabet E.
    Thomas, Sheeba K.
    Weber, Donna M.
    Munoz, Silvia C.
    Morphey, Ashley
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Orlowski, Robert Z.
    [J]. BLOOD, 2017, 130
  • [8] Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Weber, Donna
    Thomas, Sheeba K.
    Wang, Michael
    Turturro, Francesco
    Qazilbash, Muzaffar H.
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Manasanch, Elisabet E.
    Munoz, Silvia C.
    Landry, Ashley
    Mendoza, Kathleen
    Nieto, Yago
    Champlin, Richard E.
    Orlowski, Robert Z.
    [J]. BLOOD, 2015, 126 (23)
  • [9] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
    Kapoor, Prashant
    Gertz, Morie A.
    Laplant, Betsy
    Malave, Gabriella C.
    Wolfe, Eric
    Muchtar, Eli
    Siddiqui, Mustaqeem A.
    Gonsalves, Wilson I.
    Emanuel, Angie R.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Dingli, David
    Buadi, Francis K.
    Hayman, Suzanne R.
    Leung, Nelson
    Hwa, Yi L.
    Hobbs, Miriam A.
    Fonder, Amie
    Dispenzieri, Angela
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    [J]. BLOOD, 2019, 134
  • [10] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
    Zhuang, Zhe
    Tian, Ying
    Yu, Hong
    Shi, Lei
    Tian, Wei-wei
    Liu, Qinhua
    Zou, Dongmei
    Dong, Fei
    Ma, Yanping
    Feng, Ru
    Liu, Shuangjiao
    Liu, Hui
    Jing, Hongmei
    Sun, Wanling
    Ma, Liang-Ming
    Bao, Li
    Wu, Yin
    Chen, Wenming
    Zhuang, Junling
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S54 - S55